Clinical Trial Update: Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of Bortezomib and Cisplatin in patients with recurrent or metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• CISPLATIN (cisplatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: RECRUITING